ATE364631T1 - Hauptneutralisationsort des hepatitis e virus und verwendung dieses neutralisationsort in impfungverfahren und in verfahren zum screening nach neutralisationsantikörper - Google Patents

Hauptneutralisationsort des hepatitis e virus und verwendung dieses neutralisationsort in impfungverfahren und in verfahren zum screening nach neutralisationsantikörper

Info

Publication number
ATE364631T1
ATE364631T1 AT00982311T AT00982311T ATE364631T1 AT E364631 T1 ATE364631 T1 AT E364631T1 AT 00982311 T AT00982311 T AT 00982311T AT 00982311 T AT00982311 T AT 00982311T AT E364631 T1 ATE364631 T1 AT E364631T1
Authority
AT
Austria
Prior art keywords
neutralization
site
antibodies
hepatitis
virus
Prior art date
Application number
AT00982311T
Other languages
English (en)
Inventor
Darren Schofield
Suzanne Emerson
Robert Purcell
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE364631T1 publication Critical patent/ATE364631T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00982311T 1999-12-01 2000-11-30 Hauptneutralisationsort des hepatitis e virus und verwendung dieses neutralisationsort in impfungverfahren und in verfahren zum screening nach neutralisationsantikörper ATE364631T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16749099P 1999-12-01 1999-12-01

Publications (1)

Publication Number Publication Date
ATE364631T1 true ATE364631T1 (de) 2007-07-15

Family

ID=22607568

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00982311T ATE364631T1 (de) 1999-12-01 2000-11-30 Hauptneutralisationsort des hepatitis e virus und verwendung dieses neutralisationsort in impfungverfahren und in verfahren zum screening nach neutralisationsantikörper

Country Status (6)

Country Link
US (2) US6930176B2 (de)
EP (1) EP1235862B1 (de)
AT (1) ATE364631T1 (de)
AU (1) AU1936001A (de)
DE (1) DE60035221D1 (de)
WO (1) WO2001040270A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120391T2 (de) * 2000-04-07 2007-06-06 The Government of the United States of America, as represented by the Secretary, Centers for Disease Control and Prevention Verwendung von hev-polypeptiden
US7282205B2 (en) 2001-11-07 2007-10-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-hepatitis A virus antibodies
BR122015016384B8 (pt) 2001-11-08 2021-07-27 Beijing Wantai Biological Pharmacy Entpr Co Ltd polipeptídio recombinante ou isolado, molécula de ácido nucléico, kit de diagnóstico para detectar a infecção pelo vírus da hepatite e, composição de vacina, composição farmacêutica, vetor de expressão recombinante, célula hospedeira transformada e uso do polipeptídeo recombinante ou isolado

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2144855C (en) 1992-09-18 2008-09-09 Sergei A. Tsarev Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
US5563032A (en) 1992-10-21 1996-10-08 The United States Of America As Represented By The Department Of Health And Human Services Mosaic polypeptide and methods for detecting the hepatitis E virus

Also Published As

Publication number Publication date
EP1235862B1 (de) 2007-06-13
WO2001040270A2 (en) 2001-06-07
WO2001040270A3 (en) 2002-01-10
US7148323B2 (en) 2006-12-12
DE60035221D1 (de) 2007-07-26
AU1936001A (en) 2001-06-12
US6930176B2 (en) 2005-08-16
US20030211463A1 (en) 2003-11-13
EP1235862A2 (de) 2002-09-04
US20050233316A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
ATE282429T1 (de) Immunogene zusammensetzungen gegen den cck-b- gastrin-rezeptor und verfahren zur behandlung von tumoren
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
DE60042114D1 (de) Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
EP1701664A4 (de) System und verfahren zur behandlung von gewebe
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
AU2003285874A8 (en) Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
MXPA04003274A (es) Productos biologicos.
DE60223340D1 (de) Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
EP1499190A4 (de) Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE415163T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
PL376964A1 (pl) Leczenie miażdżycy tętnic przez bierne uodpornienie peptydem
DE60231475D1 (de) Materialien und methoden zur behandlung von hepatitis c
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
ATE364631T1 (de) Hauptneutralisationsort des hepatitis e virus und verwendung dieses neutralisationsort in impfungverfahren und in verfahren zum screening nach neutralisationsantikörper
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE283920T1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties